Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances

European Journal of Clinical Investigation

Volumn 26, Issue 8, 1996, Pages 692-697

  Lemne, C ^a   De Faire, U ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Fibrinogen; Fibrinolysis; Haemostatic variables; Insulin; Lipoprotein; Von Willebrand factor

Indexed keywords

FIBRINOGEN; INSULIN; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL;

EID: 0029763785     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1996.tb02155.x     Document Type: Article

References (31)

1. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
2. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987;258:1183-6.
3. Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 1990;11:444-51.
4. Qizibash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentration as risk factors for transient cerebral ischaemia and minor ischaemic strokes. Br Med J 1991;303:605-9.
5. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993;69:338-42.
6. Dotevall A, Kutti J, Teger-Nilsson A-C, Wadenvik H, Wilhelmsen L. Platelet reactivity, fibrinogen and smoking. Eur J Haematol 1987;38:55-9.
7. Rosengren A, Wilhelmsen L, Welin L, Tsipogianni A, Teger-Nilsson A-C, Wedel H. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. Br Med J 1990;300:634-8.
8. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983;31:427-36.
9. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
10. Hamsten A et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
11. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 1990;227:273-8.
12. Jansson J-H, Johansson B, Boman K, Nilsson TK. Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Int Med 1991;229:309-16.
13. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular line Hep G2. Thromb Haemostas 1988;60:491-4.
14. Kooistra T, Bosma PJ, Törs HAM, Van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989;62:723-8.
15. Stiko-Rahm A et al. Secretion of plasminogen activator inhibitor level from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990;10:1067-73.
16. Coller BS. Thrombosis and Hemostasis, 2nd edn. Philadelphia: JB Lippincott, 1987: 60-97.
17. Blann AD, Naqvi T, Waite M, McCollum CN. Von Willebrand Factor and endothelial damage in essential hypertension. J Hum Hypertens 1993;7:107-11.
18. Pedrinelli R et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994;344:14-18.
19. Smith U, Gudbjörnsdottir S, Landin K. Hypertension as a metabolic disorder - an overview. J Int Med 1991;229(Suppl. 2):1-7.
20. Lemne C, Efendic S, Hamsten A, de Faire U. Impaired glucose and insulin metabolism in borderline hypertension. Blood Pressure 1994;3:287-94.
21. Lemne C, Hamsten A, Karpe F, Nilsson-Ehle P, de Faire U. Dyslipoproteinaemic changes in borderline hypertension. Hypertension 1994;24:605-10.
22. Lemne C, Lundeberg T, Theodorsson E, de Faire U. Increased basal concentrations of plasma endothelin in borderline hypertension. J Hypertens 1994;12;1069-74.
23. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994;343:435-9.
24. Carlsson K. Lipoprotein fractionation. J Clin Pathol 1973;5(Suppl. 26):32-7.
25. Hamsten A, Walldius G, Dahlén G, Johansson B, de Faire U: Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986;59:223-5.
26. Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its fast inhibitor in plasma. Clin Chem 1986;32:482-5.
27. Amiral J, Adalbert B, Adam M. Application of enzyme immunoassay to coagulation testing. Clin Chem 1984;30:1512-16.
28. Vermylen C, de Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen. Fibrin polymerization time (FPT test). Clin Chim Acta 1973;8:418-24.
29. Gleerup G, Vind J, Winther K. Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients. Eur J Clin Invest 1995;25:266-70.
30. Julius S, Jamerson K, Meija A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk; The Tecumseh Blood Pressure Study. JAMA 1990; 264:354-58.
31. Teger-Nilsson A-C, Larsson T, Hjemdahl P, Olsson G. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of β-blockade. Circulation 1991; 84 (Suppl. VI):VI-72-VI-77.